Hyperbaric Oxygen Therapy for Wound Healing: Clinical Evidence

Chronic non-healing wounds affect approximately 6.5 million Americans annually, costing the healthcare system an estimated $25 billion per year (Wound Healing Society, 2023). For patients whose wounds resist standard treatment, hyperbaric oxygen therapy offers a clinically validated option with decades of evidence and FDA approval.

This article examines the clinical evidence behind HBOT for wound healing — including the latest 2026 research — explains who benefits most, and details what patients should expect from treatment.

Why Wounds Fail to Heal

Normal wound healing requires adequate oxygen delivery to damaged tissue. Wounds become chronic when this process breaks down:

Diabetes: High blood sugar damages blood vessels and nerves, reducing oxygen delivery to extremities. Approximately 15% of diabetic patients develop foot ulcers, and 14-24% of those require amputation (American Podiatric Medical Association, 2023)
Radiation damage: Cancer radiation therapy destroys small blood vessels in the treatment field, creating chronically hypoxic tissue that cannot support healing
Peripheral vascular disease: Narrowed or blocked arteries reduce blood flow to the legs and feet
Venous insufficiency: Poor venous return causes chronic swelling and skin breakdown
Pressure injuries: Sustained pressure cuts off blood supply to tissue, particularly in immobile patients
Surgical wounds: Some post-operative wounds fail to heal due to poor local blood supply or infection
Medication-related osteonecrosis: Certain drugs, particularly bisphosphonates and anti-angiogenic agents, can cause bone tissue death in the jaw and other areas, creating wounds that resist conventional treatment

In all these cases, the underlying problem is insufficient oxygen reaching the wound bed. This is exactly the problem HBOT is designed to address.

How HBOT Accelerates Wound Healing

HBOT addresses chronic wound hypoxia through multiple mechanisms. A 2026 narrative review published in the Journal of Clinical Medicine confirmed that HBOT increases dissolved plasma oxygen and creates a transient hyperoxic milieu that supports fibroblast activity, collagen cross-linking, angiogenesis, and host antimicrobial defenses.

Immediate Effects (During and Immediately After Each Session)

Hyperoxygenation: At 2.4 ATA with 100% oxygen, wound tissue oxygen levels increase dramatically, providing the oxygen needed for collagen synthesis and cellular repair
Vasoconstriction without hypoxia: HBOT causes blood vessel constriction (reducing edema/swelling) while paradoxically increasing tissue oxygen levels — a net benefit for swollen, waterlogged wound beds
Enhanced white blood cell function: Neutrophils require oxygen to kill bacteria. HBOT restores bactericidal capacity in hypoxic wound tissue
Improved antimicrobial defenses: The hyperoxic environment directly enhances the oxidative burst mechanism that immune cells use to destroy invading pathogens

Cumulative Effects (Over Multiple Sessions)

Angiogenesis: Repeated HBOT sessions stimulate growth of new blood vessels into the wound bed, improving long-term oxygen delivery (Thom, 2011). Recent research continues to confirm this as one of the most important therapeutic mechanisms
Fibroblast proliferation: Fibroblasts, the cells that produce collagen and build new tissue, multiply more effectively in oxygen-rich environments. The 2026 review specifically highlights fibroblast activity and collagen cross-linking as key HBOT-mediated healing pathways
Stem cell mobilization: HBOT increases circulating stem cells by up to 800% after a series of treatments (Thom et al., University of Pennsylvania, 2006), supporting tissue regeneration
Bacterial suppression: At pressures above 1.5 ATA, elevated oxygen levels become bacteriostatic, directly inhibiting the growth of common wound pathogens including Clostridium, Staphylococcus, and Pseudomonas species
Biofilm disruption: Emerging evidence suggests HBOT may help break down bacterial biofilms that protect chronic wound infections from antibiotics. Biofilms are increasingly recognized as a major barrier to chronic wound healing, and HBOT's ability to penetrate these protective matrices represents an important therapeutic advantage

Clinical Evidence: Diabetic Foot Ulcers

Diabetic foot ulcers represent the most extensively studied wound healing application of HBOT.

Meta-Analysis Results

A systematic review and meta-analysis published in Scientific Reports (2021) pooled data from controlled clinical trials:

Complete healing: 148 out of 321 patients (46%) treated with HBOT achieved complete ulcer healing, compared to 75 out of 323 patients (23%) receiving standard treatment alone
Relative benefit: HBOT approximately doubled the complete healing rate
Amputation reduction: Multiple included studies showed significant reduction in major amputation rates

2026 Updated Evidence

A January 2026 systematic review published in Cureus reaffirmed these findings, concluding that HBOT significantly increases healing rates and reduces both major and minor amputations in patients with chronic and ischemic wounds. The review noted that for patients with diabetic foot ulcers complicated by surgical infection, HBOT reduces the chance of amputation and improves the chance of healing. This latest evidence strengthens the case that HBOT remains a valuable adjunct for diabetic wound management.

Clinical Practice Guidelines

The Undersea and Hyperbaric Medical Society (UHMS) clinical practice guidelines recommend:

Adding HBOT for patients with Wagner Grade 3 or higher diabetic foot ulcers
Treatment should follow surgical debridement of infected tissue
Standard protocol: 2.0-2.4 ATA, 100% oxygen, 90-minute sessions, 5 days per week, for 30-40 sessions

Long-Term Outcomes

Research demonstrates that:

Patients receiving HBOT healed faster and remained healed at one year at higher rates than those treated without HBOT
A 2017 review in Diabetes & Metabolism confirmed that HBOT significantly reduces both the risk of amputation and the time to complete wound closure
The 2026 evidence continues to support these long-term benefits across multiple wound types

Clinical Evidence: Radiation Injury Wounds

Delayed radiation injury (also called radiation necrosis or osteoradionecrosis) occurs months to years after cancer radiation therapy. HBOT is considered a standard treatment:

How Radiation Damages Wound Healing

Radiation destroys the small blood vessels (capillaries) in the treatment field, creating a progressive condition called "obliterative endarteritis." Over time, the irradiated tissue becomes increasingly hypoxic and fibrotic, making it unable to heal from even minor trauma.

Evidence for Radiation Wound Healing

The UHMS includes delayed radiation injury as one of the 14 FDA-approved HBOT indications
Studies demonstrate that HBOT stimulates angiogenesis in irradiated tissue, increasing capillary density by 75-80% after a full treatment course
Mandibular osteoradionecrosis (jaw bone death after head/neck radiation) shows significant improvement with HBOT, with studies reporting resolution rates of 60-85% when combined with surgical intervention

Dental and Oral Surgery Applications

A 2026 narrative review in the Journal of Clinical Medicine evaluated HBOT specifically for high-risk dental indications, including osteoradionecrosis (ORN), medication-related osteonecrosis of the jaw (MRONJ), chronic osteomyelitis, poorly healing postoperative wounds, and procedures in patients with systemic comorbidities. The review found that by increasing tissue oxygen availability, HBOT may support bone and soft-tissue repair under hypoxic and chronically inflamed conditions. This is particularly relevant for cancer survivors who need dental procedures in previously irradiated tissue.

Standard Radiation Injury Protocol

Pre-surgical preparation: 20-30 HBOT sessions before any planned surgery in irradiated tissue
Post-surgical healing: 10 additional sessions after surgery
Total treatment course: 30-40 sessions at 2.0-2.4 ATA

Clinical Evidence: Skin Grafts and Flaps

HBOT is FDA-approved for supporting compromised surgical grafts and flaps, and recent research has strengthened the evidence base.

Updated Evidence from 2025-2026

A 2025 study published in Reports evaluated HBOT's role in enhancing skin graft outcomes across multiple dimensions: mechanisms, clinical evidence, and comparative efficacy. The research confirmed that HBOT significantly improves graft survival by mitigating ischemia and infection. Comparative studies show a reduction in major amputations and improved healing in complex cases, such as diabetic foot ulcers and traumatic injuries requiring grafting. See the compromised skin grafts and flaps evidence atlas for the full study-by-study evidence breakdown.

Clinical Applications

Pre-treatment of irradiated or poorly vascularized graft recipient sites improves graft survival rates
Post-operative HBOT can rescue threatened flaps by improving oxygen delivery to tissue edges
HBOT is particularly valuable when grafts are placed in compromised tissue beds where local blood supply is inadequate

Clinical Evidence: Other Wound Types

Crush Injuries

Severe crush injuries with compartment syndrome benefit from HBOT:

Reduces tissue edema through vasoconstriction
Maintains oxygen delivery to tissue at risk of necrosis
May reduce the need for fasciotomy or amputation
Time-sensitive: early HBOT intervention within 4-6 hours of injury provides the greatest benefit

Necrotizing Soft Tissue Infections

Gas gangrene and other necrotizing infections are FDA-approved HBOT indications: See the gas gangrene evidence atlas for the full study-by-study evidence breakdown.

HBOT is always used alongside surgical debridement and antibiotics
Elevated oxygen levels are directly toxic to anaerobic bacteria like Clostridium species
Studies show reduced mortality when HBOT is added to standard surgical and antibiotic treatment

Chronic Osteomyelitis

Bone infections that resist standard antibiotic treatment represent another established HBOT indication:

HBOT enhances antibiotic penetration into infected bone tissue
The hyperoxic environment supports osteoclast and osteoblast activity needed for bone remodeling
Treatment is always combined with surgical debridement and appropriate antibiotic therapy

Treatment Protocols for Wound Healing

Standard Clinical Protocol

Parameter	Typical Value
Pressure	2.0-2.4 ATA
Oxygen	100% medical-grade
Session duration	90 minutes (including compression and decompression)
Frequency	5 days per week
Total sessions	30-40 (average)
Treatment duration	6-8 weeks
Chamber type	Hard-shell (monoplace or multi-place)

Monitoring Progress

Effective HBOT wound care programs include:

Transcutaneous oxygen measurement (TCOM): Measures tissue oxygen levels before and during HBOT to confirm the wound responds to treatment. TCOM values above 200 mmHg during treatment are generally considered a positive predictor of healing
Weekly wound assessments: Photography, measurement, and clinical evaluation of healing progress
Decision points: If no measurable improvement occurs after 15-20 sessions, the treatment team reassesses the protocol
Coordinated wound care: HBOT works alongside debridement, negative pressure wound therapy, advanced dressings, offloading, and infection management

The Need for Standardized Protocols

The January 2026 review published in Cureus noted that standardized, high-quality studies with clearly defined endpoints and uniform therapeutic protocols are still needed to determine optimal indications and treatment parameters. While the overall evidence strongly supports HBOT for wound healing, there is variation in treatment protocols across different facilities and clinical trials. Patients should seek treatment at centers that follow UHMS guidelines and maintain robust outcome tracking.

Cost and Insurance Coverage

Pricing

Hospital-based programs: $350-$600 per session
Outpatient wound care centers: $200-$400 per session
Total treatment cost: $6,000-$24,000 for a 30-40 session course
Cost-effectiveness consideration: When HBOT prevents an amputation, the long-term savings are substantial — the five-year cost of a below-knee amputation (including prosthetics, rehabilitation, and ongoing care) exceeds $100,000

Insurance Coverage for Wound Healing

HBOT for chronic non-healing wounds is one of the best-covered HBOT applications:

Medicare: Covers HBOT for diabetic foot ulcers (Wagner Grade 3+), radiation injury wounds, and other FDA-approved wound indications. Patient pays approximately 20% coinsurance after meeting the Part B deductible.
Private insurance: Most major insurers cover HBOT for qualifying wounds. Typically requires documentation that the wound has not responded to at least 30 days of standard care.
Pre-authorization: Nearly always required. The wound care team handles this process.
Documentation requirements: Serial wound measurements, photographs, treatment history, and TCOM results

Who Benefits Most from HBOT for Wound Healing

Based on the clinical evidence, including the most recent 2026 reviews, the strongest candidates include:

Patients with diabetic foot ulcers classified as Wagner Grade 3 or higher
Patients with chronic wounds in previously irradiated tissue
Patients with wounds that have not responded to at least 30 days of standard wound care
Post-surgical patients with compromised grafts or flaps
Patients with medication-related osteonecrosis of the jaw (MRONJ) or osteoradionecrosis
Patients with chronic osteomyelitis resistant to antibiotic therapy alone
Patients with adequate arterial blood flow (HBOT cannot compensate for completely blocked arteries)

Who May Not Benefit

Patients with wounds caused by untreated arterial insufficiency (revascularization should be attempted first)
Patients with untreated osteomyelitis (bone infection must be addressed surgically)
Patients unable to commit to the 6-8 week treatment schedule
Patients with contraindications to HBOT (untreated pneumothorax, certain chemotherapy medications)
Patients whose wounds lack adequate blood supply to deliver the oxygen HBOT provides — a baseline TCOM assessment can help determine this

Frequently Asked Questions

How long does it take for HBOT to show wound healing results?

Most wound care programs expect measurable improvement within 15-20 sessions (3-4 weeks). Early signs include reduced wound size, improved granulation tissue, decreased drainage, and reduced pain. If no improvement is seen by session 20, the treatment team typically reassesses the approach. Complete wound closure may take the full 30-40 session course or longer.

Can HBOT heal wounds that have been open for years?

Yes, in some cases. The clinical evidence includes patients with wounds that had been non-healing for months to years. The 2021 meta-analysis included patients with chronic diabetic foot ulcers of varying duration, and HBOT approximately doubled the complete healing rate regardless of wound chronicity. However, longer-standing wounds may require more sessions and have lower overall success rates.

Is HBOT used before or after wound surgery?

Both. For radiation injury wounds, the standard protocol includes 20-30 sessions before surgery (to prepare the tissue) and 10 sessions after (to support healing). For other wound types, HBOT typically begins after initial surgical debridement and continues throughout the healing process. Your wound care team will determine the optimal sequence based on your specific wound type and clinical situation.

What happens if I miss HBOT sessions during wound treatment?

Consistency matters. The cumulative effects of HBOT — particularly angiogenesis and stem cell mobilization — depend on regular, repeated treatments. Missing occasional sessions (illness, travel) is generally manageable, but extended breaks may slow healing progress. Most protocols allow for brief interruptions without restarting the entire course.

Can I use a portable soft-shell chamber for wound healing at home?

No. Wound healing protocols require hard-shell chambers at 2.0-2.4 ATA with 100% oxygen. Soft-shell chambers reach only 1.3-1.4 ATA with ambient air, which does not achieve the pressure or oxygen levels needed for clinical wound healing. Additionally, wound healing requires physician supervision, regular wound assessments, and coordinated care that home use cannot provide.

What does the latest research say about HBOT for wound healing?

The most recent evidence, including a January 2026 systematic review, continues to support HBOT as a valuable adjunct therapy for chronic and ischemic wounds. The research reaffirms that HBOT significantly increases healing rates and reduces amputations. However, researchers also note that more standardized clinical trials with uniform protocols are needed to further refine treatment guidelines and identify optimal patient selection criteria.

The Evidence Summary

HBOT for wound healing stands on the strongest evidence base of any HBOT application. Decades of research, multiple meta-analyses, FDA approval, clinical practice guidelines, and the latest 2026 reviews all support its use for specific chronic wound types. For diabetic patients facing potential amputation, HBOT approximately doubles the chance of complete healing and significantly reduces the risk of losing a limb.

Recent research has expanded the evidence to include dental and oral surgery applications, skin graft optimization, and medication-related osteonecrosis, broadening the population of patients who may benefit from HBOT-assisted wound healing.

The key is ensuring you receive treatment at an appropriate facility, with proper patient selection, adequate monitoring, and coordinated wound care. HBOT is not a standalone treatment — it is the oxygen component of a comprehensive wound management strategy.

Quick Answer